[18F]fallypride characterization of striatal and extrastriatal D2/3 receptors in Parkinson's disease

Neuroimage Clin. 2018 Feb 10:18:433-442. doi: 10.1016/j.nicl.2018.02.010. eCollection 2018.

Abstract

Parkinson's disease (PD) is characterized by widespread degeneration of monoaminergic (especially dopaminergic) networks, manifesting with a number of both motor and non-motor symptoms. Regional alterations to dopamine D2/3 receptors in PD patients are documented in striatal and some extrastriatal areas, and medications that target D2/3 receptors can improve motor and non-motor symptoms. However, data regarding the combined pattern of D2/3 receptor binding in both striatal and extrastriatal regions in PD are limited. We studied 35 PD patients off-medication and 31 age- and sex-matched healthy controls (HCs) using PET imaging with [18F]fallypride, a high affinity D2/3 receptor ligand, to measure striatal and extrastriatal D2/3 nondisplaceable binding potential (BPND). PD patients completed PET imaging in the off medication state, and motor severity was concurrently assessed. Voxel-wise evaluation between groups revealed significant BPND reductions in PD patients in striatal and several extrastriatal regions, including the locus coeruleus and mesotemporal cortex. A region-of-interest (ROI) based approach quantified differences in dopamine D2/3 receptors, where reduced BPND was noted in the globus pallidus, caudate, amygdala, hippocampus, ventral midbrain, and thalamus of PD patients relative to HC subjects. Motor severity positively correlated with D2/3 receptor density in the putamen and globus pallidus. These findings support the hypothesis that abnormal D2/3 expression occurs in regions related to both the motor and non-motor symptoms of PD, including areas richly invested with noradrenergic neurons.

Keywords: BPND, Binding potential (nondisplaceable); CES-D, Center for Epidemiologic Studies Depression Scale; Dopamine; Fallypride; HC, Healthy controls; LEDD, Levodopa Daily Dose; MDS-UPDRS, Movement Disorders Society-United Parkinson's disease Rating Scale; MoCA, Montreal Cognitive Assessment; Neurodegeneration; PD, Parkinson's disease; PET, Positron emission tomography; Parkinson's disease; Positron emission tomography (PET); ROI, Region of Interest.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Benzamides / pharmacokinetics*
  • Brain Mapping
  • Corpus Striatum / diagnostic imaging*
  • Corpus Striatum / drug effects
  • Dopamine D2 Receptor Antagonists / pharmacokinetics*
  • Female
  • Fluorodeoxyglucose F18 / pharmacokinetics
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Parkinson Disease / diagnostic imaging*
  • Positron-Emission Tomography
  • Receptors, Dopamine D2 / metabolism*

Substances

  • Benzamides
  • Dopamine D2 Receptor Antagonists
  • Receptors, Dopamine D2
  • Fluorodeoxyglucose F18
  • fallypride